Eris targets 18-20% international growth in FY27 despite EU site snag
A corporate presentation reveals fresh FY27 guidance for the international business and confirms an EU inspection that delayed commercialisation of its EU-CDMO pipeline but left existing operations intact.
What's new
- FY27 international revenue growth guided at 18-20% with stable EBITDA margin.
- EU-GMP inspection at two sites in March 2026 led to procedural non-compliance observations.
- Commercialisation of EU-CDMO pipeline delayed; minimal impact on existing business.
Why this matters
Eris is now providing explicit international growth targets for the first time, adding modelling clarity for a segment that was previously opaque. However, the EU regulatory hit introduces a near-term overhang, suggesting the pipeline ramp-up will take longer than hoped. The domestic branded biz guidance remains unchanged at 1.3x therapy growth and 37% EBITDA margin.
What we're watching
- Timeline for closure of EU-GMP observations and re-inspection.
- FY27 execution on the international revenue target, especially EU-CDMO contribution.
- Whether domestic branded growth sustains at 1.3x therapy market growth.
The full read
Eris Lifesciences has given the street its first explicit FY27 target for the international business: 18-20% revenue growth with EBITDA margins held at FY26 levels. That is a fresh data point for a segment that investors have been trying to size up. But the same presentation also reveals that an EU-GMP inspection in March 2026 turned up procedural non-compliance observations at two manufacturing sites, delaying the EU-CDMO pipeline commercialisation. Existing operations took minimal hit. The domestic branded formulations guidance (a rehash from the Q4 concall) targets 1.3x therapy market growth and 37% EBITDA margin. The net read: international visibility improves, but a regulatory overhang tempers the excitement. The open question is how fast Eris clears those observations and gets the pipeline back on track.
Questions answered
- What is Eris Lifesciences' FY27 guidance for its international business?
- Eris targets international revenue growth of 18-20% with an EBITDA margin steady at the FY26 level.
- What happened during the EU-GMP inspection in March 2026?
- An EU regulatory inspection of two manufacturing sites concluded with procedural non-compliance observations. This has delayed the commercialisation of its EU-CDMO product pipeline, but existing business operations were minimally impacted.
- Is the domestic branded formulations guidance new?
- No, the domestic guidance of 1.3 times therapy market growth and a 37% EBITDA margin was already communicated in the fourth-quarter earnings call.
- How material is the EU inspection delay for Eris?
- The delay primarily affects new EU-CDMO product launches. Existing business is largely unaffected, and the financial impact is moderate for a mid-cap pharma company like Eris (market cap ₹20,245 cr).
- What are Eris' trailing financials?
- The company has a P/E of 32.7, ROE of 12.3%, and debt/equity of 0.85. Trailing revenue growth is 7.3% and PAT growth is 174.0%.